About CAMP4 Therapeutics Corporation CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits.

New Stocks Added to the Biotech Directories : Camp4 Therapeutics Corp (Nasdaq:CAMP ) is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein ...

Fintel reports that on November 5, 2024, Leerink Partners initiated coverage of Camp4 Therapeutics (NasdaqGM:CAMP) with a ...

CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts ...

Camp4 Therapeutics (CAMP) stock gains after J.P. Morgan and Piper Sandler launched its coverage with Overweight ...

Piper Sandler initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $18 price target The company is is pioneering ...

Leerink initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $17 price target The firm believes CMP-CPS-001, the lead ...

https://www.tipranks.com/news/the-fly/curaleaf-price-target-lowered-to-c6-50-from-c11-at-alliance-global-partners Monopar Therapeutics Inc ( (MNPR)) just unveiled an ...

Insider roster data is derived solely from the last 24 months of Form 3 & Form 4 SEC filings. Individual or entity Most recent transaction Date Shares owned as of transaction date 5AM PARTNERS VI, LLC ...

It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in ...

Seaport Therapeutics, the startup launched earlier this year by the team behind Karuna Therapeutics, has raised another $225 million just six months after its most recent fundraising round.